Bruton Tyrosine Kinase–Dependent Immune Cell Cross-talk Drives Pancreas Cancer
Andrew J. Gunderson, Megan M. Kaneda, Takahiro Tsujikawa et al. · Cancer Discovery · 2015
UNLABELLED: Pancreas ductal adenocarcinoma (PDAC) has one of the worst 5-year survival rates of all solid tumors, and thus new treatment strategies are urgently needed. Here, we report that targeting Bruton tyrosine kinase (BTK), a key B-cell and macrophage kinase, restores T cell-dependent antitumor immune responses, thereby inhibiting PDAC growth and improving responsiveness to standard-of-care chemotherapy. We report that PDAC tumor growth depends on cross-talk between B cells and FcRγ(+) tumor-associated macrophages, resulting in T(H)2-type macrophage programming via BTK activation in a PI3Kγ-dependent manner. Treatment of PDAC-bearing mice with the BTK inhibitor PCI32765 (ibrutinib) or by PI3Kγ inhibition reprogrammed macrophages toward a T(H)1 phenotype that fostered CD8(+) T-cell cytotoxicity, and suppressed PDAC growth, indicating that BTK signaling mediates PDAC immunosuppression. These data indicate that pharmacologic inhibition of BTK in PDAC can reactivate adaptive immune responses, presenting a new therapeutic modality for this devastating tumor type. SIGNIFICANCE: We report that BTK regulates B-cell and macrophage-mediated T-cell suppression in pancreas adenocarcinomas. Inhibition of BTK with the FDA-approved inhibitor ibrutinib restores T cell-dependent antitumor immune responses to inhibit PDAC growth and improves responsiveness to chemotherapy, presenting a new therapeutic modality for pancreas cancer.
Cited by 486 works. doi:10.1158/2159-8290.cd-15-0827
Authors
- Andrew J. Gunderson
- Megan M. Kaneda
- Takahiro Tsujikawa
- Abraham V. Nguyen
- Nesrine I. Affara
- Brian Ruffell
- Sara Gorjestani
- Shannon M. Liudahl
- Morgan Truitt
- Peter Olson
- Grace Kim
- Douglas Hanahan
- Margaret A. Tempero
- Brett C. Sheppard
- Bryan A. Irving
- Betty Y Chang
- Judith A. Varner
- Lisa M. Coussens
References
- Cancer statistics, 2012
- FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
- Colony-Stimulating Factor 1 Promotes Progression of Mammary Tumors to Malignancy
- Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras
- Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse
- Accessories to the Crime: Functions of Cells Recruited to the Tumor Microenvironment
- FcR γ chain deletion results in pleiotrophic effector cell defects
- Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer
- Direct evidence for the pancreatic lineage: NGN3+ cells are islet progenitors and are distinct from duct progenitors
- Endogenous oncogenic K-rasG12D stimulates proliferation and widespread neoplastic and developmental defects